Mechanism Governing the Cellular Susceptibility to Secretory Phospholipase A2

Lauren Blackburn Jensen

Brigham Young University - Provo

Follow this and additional works at: https://scholarsarchive.byu.edu/etd

Part of the Cell and Developmental Biology Commons, and the Physiology Commons

BYU ScholarsArchive Citation

Jensen, Lauren Blackburn, "Mechanism Governing the Cellular Susceptibility to Secretory Phospholipase A2" (2004). All Theses and Dissertations. 1137.

https://scholarsarchive.byu.edu/etd/1137

This Thesis is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in All Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact scholarsarchive@byu.edu, ellen_amatangelo@byu.edu.
MECHANISM GOVERNING THE CELLULAR SUSCEPTIBILITY TO
SECRETORY PHOSPHOLIPASE A₂

by

Lauren B. Jensen

A thesis submitted to the faculty of
Brigham Young University
in partial fulfillment of the requirements for the degree of

Master of Science

Department of Physiology and Developmental Biology
Brigham Young University
June 2004
This thesis has been read by each member of the following graduate committee and by majority vote has been found to be satisfactory.

Date __________________________  John D. Bell, Chair

Date __________________________  William S. Bradshaw

Date __________________________  Allan M. Judd
As chair of the candidate’s graduate committee, I have read the thesis of Lauren B. Jensen in its final form and have found that (1) its format, citations, and bibliographical style are consistent and acceptable and fulfill university and department style requirements; (2) its illustrative materials including figures, tables, and charts are in place; and (3) the final manuscript is satisfactory to the graduate committee and is ready for submission to the university library.

__________________________ __________________________________________
Date     John D. Bell
Chair, Graduate Committee

Accepted for the Department

__________________________________________
James P. Porter
Department Chair, Department of Physiology and Developmental Biology

Accepted for the College

__________________________________________
R. Kent Crookston
Dean, College of Biology and Agriculture
Secretory phospholipase A₂ (sPLA₂) is an important part of apoptosis and disposal of damaged and dying cells. However, healthy cells are not susceptible to attack by sPLA₂. Recent studies have focused on membrane properties necessary to induce susceptibility in both artificial and biological membranes. Hydrolysis of phospholipids by sPLA₂ requires at least two preliminary steps: first, adsorption of the enzyme to the cellular membrane, and second, movement of a phospholipid into the active site of the enzyme. We determined the effects of susceptibility on each of the two steps and determined the contributions changing the equilibrium constants have on susceptibility. The equilibrium constant for step one increased by a factor of 2 during susceptibility, while the equilibrium constant for step two increased by a factor of 4. The rise in the second equilibrium constant caused the majority of the change in hydrolysis rate seen during susceptibility; the influence of the first equilibrium constant is minimal. We
confirmed these results with adsorption studies (assessment of the first step). We additionally found that sPLA2 has a high affinity for the cellular membrane and that only a small percentage (3-5%) of the membrane is covered when all adsorption sites are filled by the enzyme. We proposed a mathematical model describing the mechanism of action of sPLA2, and we were able to experimentally justify the assumptions made in the model.
I would like to thank Dr. John Bell for all of his effort, time, and assistance in helping me achieve this degree. I appreciate the help from the rest of my committee, Drs. William Bradshaw and Allan Judd, as well. I am very grateful to Dr. Theodore Hazlett and Susana Sanchez for providing technical assistance and access to the two-photon scanning microscope found at the Laboratory for Fluorescence Dynamics at the University of Illinois at Champaign-Urbana. I acknowledge the generous funding from the National Science Foundation and from Bioflam. Most importantly, I would like to thank my family and especially my husband, Rick Jensen, for their love, support, and encouragement during my time here.
TABLE OF CONTENTS

Introduction..................................................................................................................1
Materials and Methods...............................................................................................3
Description of Model.....................................................................................................6
Results and Discussion.................................................................................................8
Final Comments...........................................................................................................16
References....................................................................................................................17
Figure Legends............................................................................................................22
LIST OF TABLES

1. Global analysis of effect of ionomycin on initial hydrolysis rate………………..23
2. Quantification of the number of adsorption sites for sPLA_2 on erythrocyte membranes……………………………………………………………………….25
LIST OF SCHEMES

1. Description of the two-step model.............................................................29
LIST OF FIGURES

1. Effect of enzyme concentration on the early time courses of erythrocyte hydrolysis by sPLA₂ .................................................................30

2. Extended time courses of erythrocyte hydrolysis at high and low concentrations of sPLA₂ .............................................................................31

3. Effect of ionomycin treatment on time courses of erythrocyte hydrolysis at high and low concentrations of sPLA₂ ........................................32

4. Effect of ionomycin treatment on the enzyme-concentration dependence of the initial rate of hydrolysis of erythrocytes ..................................................33

5. Global Analysis of effect of ionomycin on initial hydrolysis rate ..............34

6. Control for possible effects of fluorescamine labeling on behavior of sPLA₂ ......35

7. Visualization of adsorption of fluorescamine-labeled sPLA₂ to erythrocyte membranes with two-photon microscopy .........................................................36

8. Effect of ionomycin treatment on adsorption of sPLA₂ to erythrocyte membranes ......................................................................................................37
INTRODUCTION

Secretory phospholipase A\textsubscript{2} (sPLA\textsubscript{2}) is a low-molecular weight, extracellular protein involved in the inflammation process and cellular apoptosis (1-8). It has also been implicated in the pathology of septic shock (9). During cellular trauma, sPLA\textsubscript{2} adsorbs to the cellular membrane and hydrolyzes phospholipids at the \textit{sn}-2 position, creating fatty acids and lysophospholipids. The byproducts of phospholipid hydrolysis are further converted to inflammation factors (leukotrienes, arachidonic acid, etc.). Healthy cells resist attack by sPLA\textsubscript{2}, but damaged or dying cells are susceptible to hydrolysis (6-11). In this manner sPLA\textsubscript{2} is able to dispose of phospholipids of damaged and dying cells, but healthy cells are not affected.

Initial studies using artificial vesicles have shown that the enzyme is able to adsorb to membranes and hydrolyze the phospholipids (12,13). Additional experiments have described the properties that make artificial membranes susceptible to attack by sPLA\textsubscript{2}: the lipid composition of the membrane and the concentration of hydrolysis products, temperature, vesicle curvature (14-18). However, these experiments do not necessarily represent enzyme-membrane interactions in biological systems. Erythrocytes are a simple model for studying biological membrane susceptibility to sPLA\textsubscript{2} as they resist attack by sPLA\textsubscript{2} when healthy but changes in the membrane lead to susceptibility (11,19).

Calcium has a dual role during membrane attack by sPLA\textsubscript{2}. Extracellular calcium serves as a cofactor for the enzyme and is necessary for hydrolysis to occur (20). Intracellular calcium affects the properties of the membrane, influencing susceptibility to the enzyme (21). We will be exploiting this duality to control susceptibility and isolate
certain steps in the hydrolysis process. Barium interferes with the calcium as a cofactor (22), but still allows intracellular calcium to change the membrane properties essential for susceptibility. Ionomycin is a calcium ionophore that increases intracellular calcium, which we will use to influence the membrane properties to increase susceptibility (11). Ionomycin does not affect the function of extracellular calcium as an enzyme cofactor.

The events leading to hydrolysis of phospholipids by sPLA₂ can be described by a two-step model (shown in Scheme 1): first, adsorption of the enzyme to the cellular membrane; and second, movement of a phospholipid into the active site. Changes in either or both steps may lead to increased susceptibility. Our ultimate goal is to produce a mathematical model describing the mechanism of action of sPLA₂ and how susceptibility affects the action of the enzyme. Unpublished data from our lab showed that changing the temperature affects susceptibility through both steps in the two-step model. Additional unpublished data from our lab showed that increasing intracellular calcium concentration increases the tendency of a phospholipid to move out of the membrane and into the active site of the enzyme (the second step).

We studied the influence of increasing susceptibility on each step of the model by changing intracellular calcium concentration (by treating the cells with ionomycin). We found that the second step was greatly increased during susceptibility, while step one was only slightly changed. We were able to validate the results for step one: the effect of ionomycin treatment on adsorption individually was not significantly different than control. Additionally, we justified experimentally the assumptions made in our mathematical model. Finally, we quantified the number of sPLA₂ adsorption sites on the cell surface.
MATERIALS AND METHODS

Materials

Erythrocytes were obtained from healthy individuals receiving blood tests during physical examinations at the Brigham Young University Student Health Center. The samples were stored overnight at 4 °C in EDTA vacutainers from which patient identification was removed. The storage conditions did not influence the results (11). Erythrocytes were isolated by centrifugation, and resuspended to the original hematocrit in modified balanced salt solution (MBSS; 134 mM NaCl, 6.2 mM KCl, 1.6 mM CaCl₂, 1.2 mM MgCl₂, 18 mM HEPES, 13.6 mM glucose, pH 7.4 at 37 °C), high-barium, low-calcium, low-magnesium medium (LCBM; 134 mM NaCl, 6.2 mM KCl, 1.6 mM BaCl₂, 18 mM HEPES, 13.6 mM glucose, pH 7.4 at 37 °C) or high-barium medium (BMBSS; 134 mM NaCl, 6.2 mM KCl, 6.4 mM BaCl₂, 1.6 mM CaCl₂, 1.2 mM MgCl₂, 18 mM HEPES, 13.6 mM glucose, pH 7.4 at 37 °C).

Secretory PLA₂ was isolated from the venom of Agkistrodon piscivorus piscivorus according to published procedure (23). This form of sPLA₂ represents a reliable model for the human forms of the enzyme (9,11). Stock solutions of the enzyme (1.15 mg/ml, 1.0 mg/ml, 0.77 mg/ml, and 0.1 mg/ml) were prepared in 50 mM KCl with 3 mM NaN₃ and stored at 4 °C.

Acrylodan-labeled fatty acid-binding protein (ADIFAB) was obtained from Molecular Probes (Eugene, OR). Ionomycin was purchased from Calbiochem (La Jolla, CA) and dissolved in dimethyl sulfoxide (DMSO) at a stock concentration of 120 µM. Fluorescamine was purchased from Sigma (St. Louis, MO) and dissolved in acetone at a stock solution of 3.0 mg/ml.
**Methods**

*Membrane hydrolysis by sPLA₂ –* Release of free fatty acids from erythrocytes was assayed with ADIFAB (65 nM final concentration, excitation: 390 nm, emission: 432 nm and 505 nm). Washed erythrocytes were suspended in 2 ml MBSS in a fluorometer sample cell to a final density of approximately 1-2×10⁶ erythrocytes per ml and equilibrated at 37 °C. Fluorescence data were acquired on a photon-counting spectrofluorometer (Fluoromax (Jobin Yvon Horiba, Edison, NJ, USA)). After initiating data acquisition, ADIFAB was added at 30 s, followed by ionomycin (300 nM) or DMSO at 130 s, and sPLA₂ (21 nM-700 nM) at 730 s. Hydrolysis results were quantified by calculation of generalized polarization (GP) and fit as described (11) using statistical software (Prism 3.0 or Prism 4.0). The initial hydrolysis rate was approximated as the amount of reaction product generated at 20 s following sPLA₂ (using coefficient values from the nonlinear regression results).

*Fluorescamine labeling* – Fluorescamine (180 µM final concentration, excitation: 390 nm, emission: 485 nm) was added to sPLA₂ (1.4 µM) and allowed to react at 37 °C. Progression of the labeling reaction was monitored by fluorescence spectroscopy as described above.

*Two-photon microscopy* – Scanning two-photon excitation microscopy images were collected on an Axiovert 35 inverted microscope (Zeiss, Thornwood, NY, USA) at the Laboratory for Fluorescence Dynamics (Urbana, IL) as described previously (24). The excitation source was a titanium-sapphire laser (Coherent, Palo Alto, CA, USA) tuned to 780 nm and pumped by a frequency-doubled Nd:vanadate laser. Power was set at 80-100 mW. Secretory PLA₂ was labeled with fluorescamine as described above.
Washed erythrocytes were mixed with 1 ml BMBSS in a temperature-controlled microscopy dish (approximately 1-2×10^6 erythrocytes per ml) and allowed to equilibrate at 37 °C. Ionomycin (300 nM) or DMSO was added, and the mixture was incubated at least 5 min. To quantify adsorption, images were acquired at multiple time points before and after addition of fluorescamine-labeled sPLA₂. Total fluorescence intensity (after subtraction of a background threshold) was measured for each image. Slopes of the fluorescence trends were calculated by linear regression using image number as the independent variable and intensity as the dependent variable. The difference between the slopes of increasing fluorescence before and after addition of labeled enzyme were calculated and compared as a function of enzyme concentration.

**Adsorption site quantification** – Secretory PLA₂ was labeled with fluorescamine as described above. Washed erythrocytes were suspended in 1 ml LCBM in a microcentrifuge tube to a final density of approximately 1-2×10^6 erythrocytes per ml. Fluorescamine-labeled sPLA₂ (70 nM) was added, and the mixture was incubated at least 10 min at 37 °C. The mixture was centrifuged (G force: 15,000 g units) for 15 s, and the pellet was washed and resuspended in 2 ml LCBM. Fluorescence data were acquired on a Fluoromax. Control experiments were performed without erythrocytes or without fluorescamine-labeled sPLA₂ to measure noise.
DESCRIPTION OF MODEL

The model describing the action of sPLA₂ on the surface of membranes is shown in Scheme 1. The rate of hydrolysis \( \frac{dP}{dt} \) is given by the following:

\[
\frac{dP}{dt} = k_{cat}E_B^S
\]  

(1)

Experiments were conducted in which the concentration of cells and, therefore, the total number of binding sites for the enzyme \( M_{ST} \) were kept constant. The equilibrium constants \( K_1 \) and \( K_2 \) are defined as follows:

\[
K_1 = \frac{E_B}{(E)(M_S)}
\]  

(2)

\[
K_2 = \frac{E_B^S}{(E_B)(S)}
\]  

(3)

If we confine our analysis to the initial part of the hydrolysis time course, then \( S \) can be assumed to be a constant mole fraction of \( M_{ST} \) \( (S_0) \). Since \( S_0 \) is a constant, the apparent value of \( K_2 \) \( (K_2^*) \) is proportional to \( K_2 \) and can be used in our calculations:

\[
K_2^* = \frac{E_B^S}{E_B}
\]  

(4)

The distribution of membrane binding sites between occupied and unoccupied states is given by:

\[
M_{ST} = M_S + E_B + E_B^S
\]  

(5)

If we assume that only a small fraction of added enzyme adsorbs to the cell surface, then \( E \) can be approximated by the total enzyme concentration, \( E_T \). This assumption was verified by binding experiments described in the next section. An explicit description of the initial hydrolysis rate can be obtained by combining equations 1, 2, and 4:
\[ \frac{dP}{dt} = \frac{\alpha E_T K_1 K_2^*}{1 + E_T K_1 + E_T K_1 K_2^*} \] (6)

where \( \alpha \) is proportional to \( k_{cat} M_{ST} \).
RESULTS AND DISCUSSION

We assumed that changing membrane properties that lead to susceptibility to attack by sPLA₂ affects either or both of the two steps prior to hydrolysis described in Scheme 1. The initial hydrolysis rate of cellular membranes can be used to find the change in equilibrium constants during susceptibility. Assessment of adsorption (step one) can validate the hydrolysis kinetics results. Quantification of the number of adsorption sites can justify the assumptions made in the model, along with giving us more details about the mechanism of action of sPLA₂.

Hydrolysis kinetics

The fluorescent fatty acid-binding protein, ADIFAB, is a useful probe for studying hydrolysis, since the shape of its emission spectrum changes upon binding to free fatty acids (products of phospholipid hydrolysis). ADIFAB is excited at 390 nm and emits with a peak at 432 nm when free in solution. However, the emission curve shifts to 505 nm when ADIFAB is bound to fatty acids. Generalized polarization (GP) is a comparison between the emission curves of bound and unbound ADIFAB and is determined using equation 7.

\[ GP = \frac{b - a}{b + a} \] (7)

where \( a \) is the emission intensity at 432 nm and \( b \) is the intensity at 505 nm. An increase in GP indicates a shift toward 505 nm and, therefore, an increase in hydrolysis of phospholipids. The time courses of hydrolysis were fit to equation 8 using nonlinear regression.

\[ y = A(1 - e^{-bt}) + C(1 - e^{-Dt}) + Et + F \] (8)
where \( y \) is the amount of hydrolysis at time \( t \). Figure 1 shows a time course of hydrolysis of phospholipids using this probe at 21 nM (black squares) and 700 nM (red triangles) sPLA\(_2\). As can be seen, sPLA\(_2\) causes hydrolysis of phospholipids within the range of concentrations examined.

The model assumes that the total number of binding sites and total initial substrate concentration remain the same at all experimental conditions. However, the data in Figure 1 seem to violate this assumption. The time courses reached a “plateau” phase within 200 s that appear to become parallel, suggesting that the total amount of substrate available for hydrolysis varies with enzyme concentration. To explore this possibility, we repeated the experiments of Figure 1 for much longer periods of time (Figure 2). These long-term experiments showed that the “plateau” phase of hydrolysis seen at the end of the time courses in Figure 1 actually represented slow hydrolysis that continued for multiple hours. Consequently, at true completion of the reaction, the time courses did, in fact, converge at 70 nM (black) and 700 nM (red). Thus, these experiments validated the model’s assumption that the total amount of substrate available for hydrolysis per cell is constant.

Ionomycin treatment changed the shape of the hydrolysis time course. Cells were treated with the ionophore 10 min prior to addition of 21 nM (black squares) or 700 nM (red triangles) sPLA\(_2\) (Figure 3). The amount of hydrolysis was determined by ADIFAB. Hydrolysis increased rapidly initially and required much less time to approach a true plateau at which the hydrolysis curves at both high and low concentrations of enzyme converged.
Initial hydrolysis rate changed as a function of the concentration of sPLA₂ (Figure 1, Figure 3). Cells were treated with or without ionomycin before addition of various concentrations (21 nM, 70 nM, 210 nM, or 700 nM) of sPLA₂. Hydrolysis was measured with ADIFAB and hydrolysis curves fit to equation 8. The values of the coefficients were used to determine the rate of hydrolysis at 20 s. Twenty seconds was determined to be the earliest time at which hydrolysis measurements are reliable. Accordingly, this time point was defined as “initial hydrolysis” and used for comparison among various concentrations. Figure 4 shows the results of this comparison—red triangles: initial hydrolysis rates of ionomycin-treated cells; black squares: initial hydrolysis rates of control (untreated) cells. The hydrolysis rate of cellular membranes increased significantly with ionomycin treatment at all sPLA₂ concentrations: a two-way analysis of variance showed that treatment with ionomycin accounted for 34.3% of the total variation (p<0.0001) and increasing the enzyme concentration accounted for 14.1% of the total variation (p=0.0079). The interaction between the two terms was not significant.

The relationship between hydrolysis rate and the equilibrium constants was mathematically defined in Description of Model and can be used to determine the change in the equilibrium constants upon an increase in susceptibility for both steps in our model. Global analysis was performed on the data collected for Figure 4 using equation 6. As stated earlier, $\alpha$ is a constant that represents $k_{cat}$, or hydrolysis of the phospholipid once it has moved into the active site. We assumed that $\alpha$ was not dependent upon the level of membrane susceptibility because we assumed that once the phospholipid has moved out of the membrane and into the active site of the enzyme, it is no longer affected by the membrane properties that determine susceptibility. We, therefore, constrained $\alpha$ to
remain equal between the two conditions (ionomycin-treated cells and control cells). Table 1 and Figure 5A show the results of the global analysis (red triangles: ionomycin-treated cells; black squares: control cells). Changing the membrane properties by increasing intracellular calcium amplified the equilibrium constant for the first step ($K_1$) by a factor of two and the equilibrium constant for the second step ($K_2^*$) by a factor of four. In other words, the affinity of sPLA$_2$ for the cellular membrane doubled and the probability of a phospholipid moving into the active site of the enzyme quadrupled. Figure 5B shows the effects of this increase in the individual steps. The solid black line (and black squares) indicates the initial hydrolysis rate of control cells; the solid red line (and red triangles) indicates the initial hydrolysis rate of ionomycin-treated cells. Increasing only $K_1$ by the factor of two is indicated by the dotted line. The dotted line very closely resembles the solid black line and is within the error bars of the black squares. Increasing only $K_2^*$ by the factor of four is indicated by a dashed line. The dashed line very closely resembles the solid red line and is within the error bars of the red triangles. Thus, the increase in $K_2^*$ contributes the majority of the effect of susceptibility, while the increase in $K_1$ merely refines the curve.

*Step 1: Adsorption kinetics*

In order to study the adsorption of sPLA$_2$ to the cellular membrane, we labeled the enzyme with fluorescamine, a fluorescent probe that covalently binds to primary amines (25). Fluorescamine is fluorescent only when attached to amines; the fluorescence of residual probe is destroyed by reaction of free fluorescamine with water. Fluorescamine is excited at 390 nm and emits at 485 nm. Because labeling of sPLA$_2$ requires covalent modification, we conducted experiments to determine if this covalent
modification changed the behavior of the enzyme. Various concentrations of fluorescamine-labeled sPLA₂ (17 nM, 35 nM, and 70 nM) were added to ionomycin-treated or control erythrocytes. Hydrolysis was measured with ADIFAB and hydrolysis curves fit to equation 8. Unfortunately, ADIFAB and fluorescamine are excited and emit at the nearly identical wavelengths, changing the overall emission curve and affecting ADIFAB GP. Additionally, sPLA₂ binds to the walls of the cuvette over time, decreasing the amount of fluorescamine fluorescence. These issues complicated interpretation of the results. Figure 6A shows the results of a hydrolysis time course at 70 nM sPLA₂ (red: ionomycin-treated cells; black: control cells). Hydrolysis did occur and was greater in susceptible (ionomycin-treated) cells than in control cells. This result was made more apparent by considering the difference between the data from control and ionomycin-treated samples at 17 nM (black), 35 nM (blue), and 70 nM (red) sPLA₂ (Figure 6B). As in Figure 4, ionomycin-treated cells were initially hydrolyzed at a faster rate than control cells (seen by a positive difference) at all enzyme concentrations. Additionally, hydrolysis by fluorescamine-labeled sPLA₂ increased with increasing enzyme concentration (Figure 6B), similar to the results seen in Figure 3. Hence, covalent labeling of sPLA₂ with fluorescamine did not change the enzyme’s general behavior toward cell membranes.

To determine the nature of adsorption of the enzyme to a cellular membrane, we observed fluorescence before and after adding fluorescamine-labeled sPLA₂ (Figure 7). Panel A is a field of untreated cells; Panel B is the same field of cells after adding 35 nM fluorescamine-labeled sPLA₂; Panel C is the same field 6 min after adding 2.9 µM unlabeled sPLA₂. The amount of fluorescence did not decrease after adding unlabeled
enzyme, indicating that desorption of sPLA₂ from the cellular membrane was very slow or that the enzyme bound nonspecifically. To determine the specificity of binding, we reversed the order of addition: 700 nM unlabeled sPLA₂ 21 min before 70 nM fluorescamine-labeled sPLA₂. Panel D shows the results of this order of addition: the fluorescamine-labeled sPLA₂ was not able to compete for the adsorption sites already filled by unlabeled enzyme. Thus, adsorption of sPLA₂ to the cellular membrane appeared to be specific and long-lived.

The influence of increasing membrane susceptibility on adsorption of the enzyme to the cell surface was also viewed through two-photon microscopy. We treated cells with or without ionomycin and acquired multiple images of the same field before and after addition of 14 nM or 70 nM fluorescamine-labeled sPLA₂. Total intensity was calculated for each image and plotted as a function of total number of scans. The slope for increasing fluorescence was determined through linear regression. The fluorescence slope before addition of labeled enzyme constituted an increase in autofluorescence from the power of the microscope. The fluorescence slope after addition of labeled enzyme, if higher than the fluorescence slope before addition of labeled enzyme, signified adsorption of labeled enzyme to the cellular membrane. We determined the normalized difference between the fluorescence slopes before and after addition of labeled enzyme (see equation 9).

$$\frac{S_B - S_A}{S_B}$$

where $S_B$ represents the fluorescence slope before addition of labeled enzyme and $S_A$ represents the fluorescence slope after addition of labeled enzyme. The normalized difference was plotted as a function of increasing enzyme concentration (Figure 8—red
triangles: ionomycin-treated cells; black squares: control cells). The amount of adsorption did not significantly increase in susceptible cells compared to control cells. Two-way analysis of variance revealed that the effect of enzyme concentration explained 48.8% of the variation seen (p=0.013), while the effects of ionomycin could rationalize only 1.2% of the variation (p=0.57). Thus, the increase in fluorescence was accounted for by the amount of enzyme added; ionomycin did not significantly increase the adsorption of sPLA₂ to the cellular membrane. The interaction between two terms was almost significant (p=0.2); a larger sample size may lead to a significant interaction term. These data justify our conclusion from the global analysis of hydrolysis kinetics that a change in $K_1$ does not significantly contribute to susceptibility.

Quantification of the number of sPLA₂ adsorption sites on the cell surface

Similar experiments were used to quantify the number of sPLA₂ binding sites on the cellular membrane. We incubated cells in a “calcium-free” (barium replaced calcium) buffer with 70 nM fluorescamine-labeled sPLA₂. We centrifuged the suspension and measured the fluorescence of the washed pellet. Control experiments were conducted without erythrocytes or without labeled enzyme to measure background noise. The amount of fluorescence in the washed pellet is proportional to the amount of labeled enzyme adsorbed to the cellular membrane. The potential number of binding sites was determined by comparing the total surface area of the enzyme to the total surface area of an erythrocyte and assuming that the surface of the erythrocyte was covered by enzyme (26,27). Table 2 compares the measured number of binding sites to the potential number of binding sites. Our measurements suggested that only 2-4% of the erythrocyte membrane is covered by sPLA₂.
Our results estimated that $2.68 \times 10^5$ enzymes are adsorbed to each cell. We added approximately $4.0 \times 10^6$ cells per 2 ml cuvette, totaling $1.072 \times 10^{12}$ enzymes adsorbed per 2 ml cuvette. When we added 700 nM sPLA$_2$ to the 2 ml cuvette, we added approximately $8.43 \times 10^{14}$ enzyme molecules per 2 ml cuvette. Thus, 0.172% of the enzyme added was adsorbed to the cells. Even if the cell were completely covered with sPLA$_2$, $3.4 \times 10^{13}$ enzymes, or 4.03% of the total enzyme added, would be adsorbed per sample. Thus, our assumption that $E$ can be approximated by $E_T$ is justified.
**FINAL COMMENTS**

Our ultimate goal is to define a mathematical model that describes the mechanism of action of sPLA$_2$ and explains susceptibility within that mechanism of action. These results suggest that our two-step model applies to biological systems. We were able to validate the assumption that $M_{ST}$ remains constant and that $E$ can be approximated by $E_T$. Additionally, we were able to resolve the contributions of each step ($K_I$ and $K_2^*$) on the level of cellular susceptibility using our model. This study argues that the model is sufficient to explain the mechanism of action of sPLA$_2$ toward both resistant and susceptible membranes.
Reference List


hydrolysis by secretory phospholipase A(2) during early phase of apoptosis *Biochim.Biophys.Acta* **1484**, 163-174


Properties and Susceptibility to Secretory Phospholipase A2

*Biochemistry* 41, 13982-13988


Table 1: Global analysis of effect of ionomycin on initial hydrolysis rate.

Values of $K_1$, $K_2$, and $\alpha$ for susceptible and control erythrocytes obtained during the global analysis for Figure 5.
Table 1

<table>
<thead>
<tr>
<th></th>
<th>Control cells</th>
<th>Ionomycin-treated cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\alpha$</td>
<td>0.08965</td>
<td>0.08965</td>
</tr>
<tr>
<td>$K_1$ (nM$^{-1}$)</td>
<td>0.008508</td>
<td>0.01746</td>
</tr>
<tr>
<td>$K_2$ $^*$</td>
<td>0.7099</td>
<td>2.888</td>
</tr>
</tbody>
</table>
Table 2. Quantification of the number of adsorption sites for sPLA2 on erythrocyte membranes. Theoretical binding sites assume complete coating of the cell by enzyme as calculated by the ratio of the surface area of the cell to the surface area of sPLA2. The measured number of sites was obtained by quantifying the amount of fluorescamine-labeled sPLA2 retained following centrifugation and washing of cells labeled as shown in Figure 7.
Table 2

<table>
<thead>
<tr>
<th></th>
<th>Number of sPLA$_2$ binding sites per cell</th>
<th>Percentage of cell covered by sPLA$_2$</th>
</tr>
</thead>
<tbody>
<tr>
<td>theoretical</td>
<td>8.5$\times$10$^6$</td>
<td>100%</td>
</tr>
<tr>
<td>measured</td>
<td>2.7$\times$10$^5$ (SE=6.8$\times$10$^4$)</td>
<td>2-4%</td>
</tr>
</tbody>
</table>
FIGURE LEGENDS

**Scheme 1: Description of the two-step model.** Secretory PLA2 requires at least two steps prior to hydrolysis: first, free enzyme \((E)\) adsorbs to adsorption sites on the membrane \(M_s\) to become bound enzyme \((E_B)\); and second, a phospholipid \((S)\) moves from the membrane into the active site of the enzyme \((E_B^S)\). Ultimately, hydrolysis of the phospholipid occurs, creating free fatty acid and lysophospholipid \((P)\). The enzyme remains bound. Equilibrium constants for the two steps are given as \(K_1\) and \(K_2\) and the hydrolysis rate constant is given by \(k_{cat}\).

**Figure 1:** Effect of enzyme concentration on the early time courses of erythrocyte hydrolysis by sPLA2. Control erythrocytes were incubated with 21 nM (black squares) or 700 nM (red triangles) sPLA2 for 300 s, and hydrolysis was assayed by ADIFAB fluorescence as described in Materials and Methods. Hydrolysis was quantified as GP and curves were obtained with nonlinear regression (as described in the text). Each datum represents the mean ± S.E. of data from seven blood samples.

**Figure 2:** Extended time courses of erythrocyte hydrolysis at high and low concentrations of sPLA2. Control erythrocytes were incubated with 70 nM (black) or 700 nM (red) sPLA2 for 1 to 3 h and hydrolysis assayed as described for Figure 1.

**Figure 3:** Effect of ionomycin treatment on time courses of erythrocyte hydrolysis at high and low concentrations of sPLA2. The experiments of Figure 1 were repeated using ionomycin-treated erythrocytes (see Materials and Method). Each datum represents the mean ± S.E. of data from seven blood samples.

**Figure 4:** Effect of ionomycin treatment on the enzyme-concentration dependence of the initial rate of hydrolysis of erythrocytes. Various concentrations
(21 nM, 70 nM, 210 nM, and 700 nM) sPLA2 were added to ionomycin-treated (red triangles) or control erythrocytes (black squares) and hydrolysis assessed as in Figure 1. The initial rates of hydrolysis were ascertained from time courses such as those shown in Figures 1 and 3 and analyzed as explained in Materials and Methods. Each datum represents the mean ± S.E. of data from seven blood samples.

**Figure 5: Global Analysis of effect of ionomycin on initial hydrolysis rate.**

The data obtained for Figure 4 were analyzed with global analysis (as described in the text) based on the relationship between hydrolysis rate and equilibrium constants (mathematically defined in Description of the Model). Panel A: Hydrolysis curves obtained by global analysis with $\alpha$ held constant (red: ionomycin-treated erythrocytes; black: control erythrocytes). Panel B: The contributions to susceptibility of increasing each equilibrium constant separately (red: ionomycin-treated erythrocytes; solid black: control erythrocytes; dotted black: increasing $K_1$ by a factor of 2; dashed black: increasing $K_2$ by a factor of 4).

**Figure 6: Control for possible effects of fluorescamine labeling on behavior of sPLA2.** Fluorescamine-labeled sPLA2 was added to ionomycin-treated or control erythrocytes and hydrolysis was assayed as described in Figure 1. Panel A: Sample time course of hydrolysis (red: ionomycin-treated erythrocytes; black: control erythrocytes). Panel B: Differences between hydrolysis of ionomycin-treated erythrocytes and hydrolysis of control erythrocytes at 18 nM (black), 35 nM (blue), and 70 nM (red) sPLA2.

**Figure 7: Visualization of adsorption of fluorescamine-labeled sPLA2 to erythrocyte membranes with two-photon microscopy.** Panel A: baseline fluorescence
prior to addition of labeled sPLA₂. Panel B: same sample following addition of 35 nM fluorescamine-labeled sPLA₂. Panel C: same sample as B 6 min following addition of 2.9 µM unlabeled sPLA₂. Panel D: new sample with 700 nM unlabeled sPLA₂ added 21 min prior to 70 nM labeled sPLA₂. Experiments were conducted in buffer containing barium to inhibit extraction and hydrolysis of membrane phospholipids using the two-photon procedure described in Materials and Methods.

Figure 8: Effect of ionomycin treatment on adsorption of sPLA₂ to erythrocyte membranes. Various concentrations (0, 14 nM, or 70 nM) of fluorescamine-labeled sPLA₂ were added to ionomycin-treated or control erythrocytes and images acquired as in Figure 7. The amount of fluorescence attributed to adsorption of labeled sPLA₂ was quantified as described in Materials and Methods. Two-way analysis of variance revealed that the effect of enzyme concentration was significant (p = 0.013), but the effects of ionomycin were not (p = 0.57). Each datum represents the mean ± S.E., n = 1 to 4 blood samples.
Scheme 1

\[ E + M_S \xrightarrow{k_1} E_B \xrightarrow{k_2} E_B^s \xrightarrow{k_{cat}} E_B + P \]
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

(A) Activity of ADIPase GP (hydrolysis) over time for Ionomycin treated and DMSO treated samples.

(B) Excess Fatty Acid Release over time for 70 nM sPLA2, 35 nM sPLA2, and 17 nM sPLA2.
Figure 7
Figure 8